Publisher
Springer International Publishing
Reference18 articles.
1. Alexandraki, K. I., Philippou, A., Boutzios, G., Theohari, I., Koutsilieris, M., Delladetsima, I. K., et al. (2017). IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms. Oncotarget, 8(45), 79003–79011.
2. Chan, J., & Kulke, M. (2014). Targeting the mTOR signaling pathway in neuroendocrine tumors. Current Treatment Options in Oncology, 15(3), 365–379.
3. Cooke, D., Divall, S., & Radovick, S. (2019). Normal and aberrant growth. In S. Melmed, R. Koenig, C. Rosen, R. Auchus, & A. Goldfine (Eds.), Williams textbook of endocrinology (pp. 948–958). Amsterdam: Elsevier.
4. Evers, B. M., Ishizuka, J., Townsend, C. M., Jr., & Thompson, J. C. (1994). The human carcinoid cell line, BON. A model system for the study of carcinoid tumors. Annals of the New York Academy of Sciences, 733, 393–406.
5. Falletta, S., Partelli, S., Rubini, C., Nann, D., Doria, A., Marinoni, I., et al. (2016). mTOR inhibitors response and mTOR pathway in pancreatic neuroendocrine tumors. Endocrine-Related Cancer, 23(11), 883–891.